Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;13(3):345-353.
doi: 10.1136/spcare-2022-003684. Epub 2022 Jul 27.

Cancer survivors and neurotoxic chemotherapy: hearing loss and tinnitus

Steven Cheung  1 , Jennifer Henderson-Sabes  1 , Judith Mastick  2 , Gary Abrams  1 , Karin Snowberg  2 , Emely Alfaro  3 , Marisa Quinn  3 , Steven Paul  2 , Bruce Cooper  2 , Margaret Wallhagen  2 , Yvette Conley  4 , Jon Levine  1 , Christine Miaskowski  5
Affiliations

Cancer survivors and neurotoxic chemotherapy: hearing loss and tinnitus

Steven Cheung et al. BMJ Support Palliat Care. 2023 Sep.

Abstract

Objectives: Little is known about hearing loss and tinnitus associated with neurotoxic chemotherapy. Study evaluated for differences in occurrence rates and effects of hearing loss and tinnitus in survivors who received a platinum alone, a taxane alone or a platinum and taxane containing regimen.

Methods: Total of 273 survivors with breast, gastrointestinal, gynaecological or lung cancer completed self-report measures of hearing loss and tinnitus and had an audiometric assessment that obtained pure tone air conduction thresholds bilaterally at frequencies of between 0.25 kHz to 16.0 kHz. To adjust for age-related and gender-related changes in hearing, each survivor's audiogram was evaluated using the National Health and Nutrition Examination Survey-modified Occupational Safety and Health Administration standards. Survivor was classified as having hearing loss if at any frequency they scored poorer than the 50th percentile for their age and gender. Survivors were categorised as having tinnitus if they reported that for >10% of their time awake, they were consciously aware of their tinnitus. Differences among the chemotherapy groups were evaluated using parametric and non-parametric tests.

Results: For most of the demographic and clinical characteristics, no differences were found among the three chemotherapy groups. Occurrence rates for audiogram-confirmed hearing loss ranged from 52.3% to 71.4%. Occurrence rates for tinnitus ranged from 37.1% to 40.0%. No differences were found among the three chemotherapy groups in the occurrence rates or effects of hearing loss and tinnitus.

Conclusion: These findings suggest that regardless of the chemotherapy regimen common mechanistic pathway(s) may underlie these two neurotoxicities.

Keywords: Cancer; Clinical assessment; Supportive care; Survivorship; Symptoms and symptom management.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1A –
Figure 1A –
Differences in the percentage of survivors who self-reported hearing loss across the three chemotherapy regimens (p=0.861).
Figure 1B –
Figure 1B –
Differences in the percentage of survivors with audiogram-confirmed hearing loss across the three chemotherapy regimens (p=0.104).
Figure 2A –
Figure 2A –
Differences in the percentage of survivors who self-reported tinnitus across the three chemotherapy regimens (p=0.707).
Figure 2B –
Figure 2B –
Differences in the percentage of survivors with tinnitus defined as the occurrence of tinnitus being present at least 5 minutes per day for 4 days per week across the three chemotherapy regimens (p=0.951).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Romano A, Capozza MA, Mastrangelo S, et al. Assessment and management of platinum-related ototoxicity in children treated for cancer. Cancers (Basel) 2020;12(5) doi: 10.3390/cancers12051266 [published Online First: 2020/05/21] - DOI - PMC - PubMed
    1. Biro K, Noszek L, Prekopp P, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 2006;70(3):177–84. doi: 10.1159/000093776 [published Online First: 2006/06/08] - DOI - PubMed
    1. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77(8):1355–62. doi: 10.1038/bjc.1998.226 [published Online First: 1998/05/14] - DOI - PMC - PubMed
    1. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25(6):708–14. doi: 10.1200/JCO.2006.08.9599 [published Online First: 2007/01/18] - DOI - PubMed
    1. Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 2016;34(23):2712–20. doi: 10.1200/JCO.2016.66.8822 [published Online First: 2016/06/30] - DOI - PMC - PubMed